139 related articles for article (PubMed ID: 31913261)
21. Outcomes for patients with systemic light chain amyloidosis and Mayo stage 3B disease.
Theodorakakou F; Briasoulis A; Fotiou D; Petropoulos I; Georgiopoulos G; Lama N; Kelekis N; Repasos E; Migkou M; Stamatelopoulos K; Dimopoulos MA; Kastritis E
Hematol Oncol; 2023 Oct; 41(4):725-732. PubMed ID: 36974438
[TBL] [Abstract][Full Text] [Related]
22. Treatment patterns and outcome following initial relapse or refractory disease in patients with systemic light chain amyloidosis.
Tandon N; Sidana S; Gertz MA; Dispenzieri A; Lacy MQ; Buadi FK; Dingli D; Fonder AL; Hobbs MA; Hayman SR; Gonsalves WI; Hwa YL; Kapoor P; Kyle RA; Leung N; Go RS; Lust JA; Russell SJ; Zeldenrust SR; Rajkumar SV; Kumar SK
Am J Hematol; 2017 Jun; 92(6):549-554. PubMed ID: 28314084
[TBL] [Abstract][Full Text] [Related]
23. High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin Deposition Disease.
Batalini F; Econimo L; Quillen K; Sloan JM; Sarosiek S; Brauneis D; Havasi A; Stern L; Dember LM; Sanchorawala V
Biol Blood Marrow Transplant; 2018 Jan; 24(1):127-132. PubMed ID: 28865972
[TBL] [Abstract][Full Text] [Related]
24. Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation.
Sidiqi MH; Aljama MA; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dispenzieri A; Dingli D; Leung N; Gonsalves WI; Kumar SK; Kapoor P; Kourelis TV; Hogan WJ; Gertz MA
Blood Adv; 2018 Apr; 2(7):769-776. PubMed ID: 29615413
[TBL] [Abstract][Full Text] [Related]
25. Clinical presentation and prognosis of light-chain amyloidosis patients with unmeasurable free light-chain levels.
Qiu Y; Zhang CL; Shen KN; Su W; Feng J; Zhang L; Cao XX; Li J
Ann Hematol; 2018 Dec; 97(12):2465-2470. PubMed ID: 30056579
[TBL] [Abstract][Full Text] [Related]
26. Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up.
Hegenbart U; Bochtler T; Benner A; Becker N; Kimmich C; Kristen AV; Beimler J; Hund E; Zorn M; Freiberger A; Gawlik M; Goldschmidt H; Hose D; Jauch A; Ho AD; Schönland SO
Haematologica; 2017 Aug; 102(8):1424-1431. PubMed ID: 28522573
[TBL] [Abstract][Full Text] [Related]
27. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis.
Palladini G; Hegenbart U; Milani P; Kimmich C; Foli A; Ho AD; Vidus Rosin M; Albertini R; Moratti R; Merlini G; Schönland S
Blood; 2014 Oct; 124(15):2325-32. PubMed ID: 25115890
[TBL] [Abstract][Full Text] [Related]
28. Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study.
Kikukawa Y; Yuki H; Hirata S; Ide K; Nakata H; Miyakawa T; Matsuno N; Nosaka K; Yonemura Y; Kawaguchi T; Hata H; Mitsuya H; Okuno Y
Int J Hematol; 2015 Feb; 101(2):133-9. PubMed ID: 25430082
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis.
Kastritis E; Gavriatopoulou M; Roussou M; Bagratuni T; Migkou M; Fotiou D; Ziogas DC; Kanellias N; Eleutherakis-Papaiakovou E; Dialoupi I; Ntanasis-Stathopoulos I; Spyropoulou-Vlachou M; Psimenou E; Gakiopoulou H; Marinaki S; Papadopoulou E; Ntalianis A; Terpos E; Dimopoulos MA
Amyloid; 2018 Dec; 25(4):234-241. PubMed ID: 30663408
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis.
Lamm W; Willenbacher W; Lang A; Zojer N; Müldür E; Ludwig H; Schauer-Stalzer B; Zielinski CC; Drach J
Ann Hematol; 2011 Feb; 90(2):201-6. PubMed ID: 20821326
[TBL] [Abstract][Full Text] [Related]
31. [Analysis of clinical characteristics and outcome of patients with very high risk primary immunoglobulin light-chain amyloidosis].
Feng J; Huang XF; Zhang CL; Shen KN; Zhang CL; Sun J; Tian Z; Cao XX; Zhang L; Zhou DB; Li J
Zhonghua Xue Ye Xue Za Zhi; 2017 Feb; 38(2):107-111. PubMed ID: 28279033
[No Abstract] [Full Text] [Related]
32. Minimal residual disease in systemic light chain amyloidosis: a systematic review and meta-analysis.
Li X; Yu Y; Yu H; Chen M; Zhang X; Wu Y
J Cancer Res Clin Oncol; 2024 Apr; 150(4):193. PubMed ID: 38619663
[TBL] [Abstract][Full Text] [Related]
33. Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis.
Premkumar VJ; Lentzsch S; Pan S; Bhutani D; Richter J; Jagannath S; Liedtke M; Jaccard A; Wechalekar AD; Comenzo R; Sanchorawala V; Royer B; Rosenzweig M; Valent J; Schönland S; Fonseca R; Wong S; Kapoor P
Blood Cancer J; 2021 Jan; 11(1):10. PubMed ID: 33431806
[TBL] [Abstract][Full Text] [Related]
34. Outcomes of patients with AL amyloidosis and low serum free light chain levels at diagnosis.
Nguyen VP; Rosenberg A; Mendelson LM; Comenzo RL; Varga C; Sanchorawala V
Amyloid; 2018 Sep; 25(3):156-159. PubMed ID: 30032640
[TBL] [Abstract][Full Text] [Related]
35. A study from The Mayo Clinic evaluated long-term outcomes of kidney transplantation in patients with immunoglobulin light chain amyloidosis.
Heybeli C; Bentall A; Wen J; Alexander MP; Buadi FK; Cosio FG; Dean PG; Dispenzieri A; Dingli D; El Ters M; Gertz MA; Hatem A; Kapoor P; Khamash H; Kourelis T; Kumar S; Lorenz EC; Mai M; Muchtar E; Murray DL; Prieto M; Schinstock CA; Stegall MD; Warsame R; Leung N
Kidney Int; 2021 Mar; 99(3):707-715. PubMed ID: 32712168
[TBL] [Abstract][Full Text] [Related]
36. Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis.
Gustine JN; Staron A; Mendelson L; Joshi T; Gopal DM; Siddiqi OK; Ruberg FL; Sanchorawala V
Blood Adv; 2023 Oct; 7(20):6080-6091. PubMed ID: 37581513
[TBL] [Abstract][Full Text] [Related]
37. Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria.
Kimmich CR; Terzer T; Benner A; Dittrich T; Veelken K; Carpinteiro A; Hansen T; Goldschmidt H; Seckinger A; Hose D; Jauch A; Wörner S; Beimler J; Müller-Tidow C; Hegenbart U; Schönland SO
Blood; 2020 Apr; 135(18):1517-1530. PubMed ID: 32107537
[TBL] [Abstract][Full Text] [Related]
38. Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis.
Cohen OC; Brodermann MH; Blakeney IJ; Mahmood S; Sachchithanantham S; Ravichandran S; Law S; Lachmann HJ; Whelan CJ; Popat R; Rabin N; Yong K; Kyriakou C; Shah R; Cheesman S; Worthington S; Hawkins P; Gillmore JD; Wechalekar AD
Amyloid; 2020 Sep; 27(3):200-205. PubMed ID: 32408823
[No Abstract] [Full Text] [Related]
39. Bortezomib-Containing Regimens for the Treatment of Newly Diagnosed and Relapsed Amyloid Light Chain Amyloidosis: A Single-Center Experience.
Jimenez-Zepeda VH; Duggan P; Neri P; Bahlis NJ
Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e79-84. PubMed ID: 27101985
[TBL] [Abstract][Full Text] [Related]
40. Organ responses with daratumumab therapy in previously treated AL amyloidosis.
Chung A; Kaufman GP; Sidana S; Eckhert E; Schrier SL; Lafayette RA; Arai S; Witteles RM; Liedtke M
Blood Adv; 2020 Feb; 4(3):458-466. PubMed ID: 32027745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]